Arovella Therapeutics Limited (AU:ALA)
ASX:ALA
Total Valuation
Arovella Therapeutics Limited has a market cap or net worth of AU$83.30M. The enterprise value is AU$65.14M.
Market CapAU$83.30M
Enterprise ValueAU$65.14M
Share Statistics
Arovella Therapeutics Limited has 1,207,183,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,207,183,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Arovella Therapeutics Limited’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -31.21%.
Return on Equity (ROE)-0.37
Return on Assets (ROA)-0.35
Return on Invested Capital (ROIC)-31.21%
Return on Capital Employed (ROCE)-0.56
Revenue Per Employee5.04K
Profits Per Employee0.00
Employee Count27
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arovella Therapeutics Limited is ―. Arovella Therapeutics Limited’s PEG ratio is 0.54.
PE Ratio―
PS Ratio806.87
PB Ratio5.47
Price to Fair Value5.47
Price to FCF-14.94
Price to Operating Cash Flow-12.27
PEG Ratio0.54
Income Statement
In the last 12 months, Arovella Therapeutics Limited had revenue of 136.00K and earned -7.51M in profits. Earnings per share was -0.01.
Revenue136.00K
Gross Profit136.00K
Operating Income-11.20M
Pretax Income-7.51M
Net Income-7.51M
EBITDA-11.10M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -6.82M and capital expenditures -101.95K, giving a free cash flow of -6.93M billion.
Operating Cash Flow-6.82M
Free Cash Flow-6.93M
Free Cash Flow per Share>-0.01
Dividends & Yields
Arovella Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change-1.43%
50-Day Moving Average0.08
200-Day Moving Average0.09
Relative Strength Index (RSI)34.41
Average Volume (3m)1.58M
Important Dates
Arovella Therapeutics Limited upcoming earnings date is Sep 2, 2026, TBA (Confirmed).
Last Earnings DateFeb 19, 2026
Next Earnings DateSep 2, 2026
Ex-Dividend Date―
Financial Position
Arovella Therapeutics Limited as a current ratio of 14.18, with Debt / Equity ratio of 0.00%
Current Ratio14.18
Quick Ratio14.18
Debt to Market Cap0.00
Net Debt to EBITDA1.88
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Arovella Therapeutics Limited has paid -3.30M in taxes.
Income Tax-3.30M
Effective Tax Rate0.44
Enterprise Valuation
Arovella Therapeutics Limited EV to EBITDA ratio is -8.01, with an EV/FCF ratio of -12.10.
EV to Sales653.37
EV to EBITDA-8.01
EV to Free Cash Flow-12.10
EV to Operating Cash Flow-12.82
Balance Sheet
Arovella Therapeutics Limited has AU$19.37M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$19.37M billion.
Cash & Marketable SecuritiesAU$19.37M
Total DebtAU$0.00
Net CashAU$19.37M
Net Cash Per ShareAU$0.02
Tangible Book Value Per ShareAU$0.02
Margins
Gross margin is 101.79%, with operating margin of -8237.35%, and net profit margin of -5521.45%.
Gross Margin101.79%
Operating Margin-8237.35%
Pretax Margin-5521.45%
Net Profit Margin-5521.45%
EBITDA Margin-8158.46%
EBIT Margin-8237.35%
Analyst Forecast
The average price target for Arovella Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast700.00%
EPS Growth Forecast26.88%